Illumina Inc. | Balance Sheet

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
1,166
1,338
1,386
1,559
2,145
3,512
Total Accounts Receivable
239
289
386
381
411
514
Inventories
154
191
271
300
333
386
Other Current Assets
59
71
54
78
91
78
Total Current Assets
1,618
1,890
2,097
2,318
2,980
4,490
Net Property, Plant & Equipment
203
265
343
713
931
1,075
Total Investments and Advances
22
37
57
57
266
260
Intangible Assets
1,054
1,039
1,026
1,019
946
1,016
Other Assets
34
58
31
50
46
48
Total Assets
3,019
3,340
3,688
4,281
5,257
6,959
ST Debt & Current Portion LT Debt
29
304
75
1
10
Accounts Payable
74
83
139
138
160
Income Tax Payable
30
39
44
32
50
Other Current Liabilities
189
296
352
533
526
Total Current Liabilities
322
722
610
705
746
Long-Term Debt
840
987
1,016
1,048
1,182
Provision for Risks & Charges
133
-
-
-
-
Deferred Taxes
88
50
135
123
88
Other Liabilities
191
168
181
214
360
Total Liabilities
1,486
1,877
1,807
1,966
2,288
Common Equity (Total)
1,533
1,463
1,849
2,197
2,749
Total Shareholders' Equity
1,533
1,463
1,849
2,197
2,749
Total Equity
1,533
1,463
1,881
2,314
2,969
Liabilities & Shareholders' Equity
3,019
3,340
3,688
4,281
5,257
Accumulated Minority Interest
-
-
33
117
220

About Illumina

View Profile
Address
5200 Illumina Way
San Diego California 92122
United States
Employees -
Website http://www.illumina.com
Updated 07/08/2019
Illumina, Inc. engages in the development and manufacture of integrated systems for the analysis of genetic variation and function. It operates through the Core Illumina and Consolidated Variable Interest Entity segments (VIE). The Core Illumina segment serve customers in the research, clinical and applied markets, and enable the adoption of a genomic solutions.